Seer to Report First Quarter 2025 Financial Results on May 13, 2025
Seer Inc (Nasdaq: SEER), a life sciences company focused on proteomics platform commercialization, has scheduled its first quarter 2025 financial results announcement for May 13, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section at investor.seer.bio, where a replay will also be available after the event.
Seer Inc (Nasdaq: SEER), un'azienda nel settore delle scienze della vita specializzata nella commercializzazione di piattaforme proteomiche, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 13 maggio 2025. La società terrà una conference call e una diretta web alle 13:30 ora del Pacifico / 16:30 ora dell'Est nello stesso giorno. Gli investitori potranno seguire la diretta streaming nella sezione Investor su investor.seer.bio, dove sarà disponibile anche la registrazione dopo l'evento.
Seer Inc (Nasdaq: SEER), una empresa de ciencias de la vida enfocada en la comercialización de plataformas de proteómica, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a la 1:30 p.m. hora del Pacífico / 4:30 p.m. hora del Este ese mismo día. Los inversores podrán acceder a la transmisión en vivo a través de la sección Investor en investor.seer.bio, donde también estará disponible la repetición después del evento.
Seer Inc (나스닥: SEER)는 프로테오믹스 플랫폼 상용화에 중점을 둔 생명과학 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일로 예정하고 있습니다. 같은 날 오후 1시 30분 태평양 시간 / 오후 4시 30분 동부 시간에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 investor.seer.bio의 Investor 섹션을 통해 라이브 웹캐스트에 접속할 수 있으며, 행사 후에는 다시보기도 제공됩니다.
Seer Inc (Nasdaq : SEER), une entreprise des sciences de la vie spécialisée dans la commercialisation de plateformes de protéomique, a programmé l'annonce des résultats financiers du premier trimestre 2025 pour le 13 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 13h30 heure du Pacifique / 16h30 heure de l'Est le même jour. Les investisseurs pourront accéder à la diffusion en direct via la section Investor sur investor.seer.bio, où un replay sera également disponible après l'événement.
Seer Inc (Nasdaq: SEER), ein Unternehmen aus dem Bereich der Lebenswissenschaften mit Fokus auf die Kommerzialisierung von Proteomik-Plattformen, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 geplant. Am selben Tag wird das Unternehmen um 13:30 Uhr Pazifischer Zeit / 16:30 Uhr Östlicher Zeit eine Telefonkonferenz und einen Webcast veranstalten. Investoren können den Live-Webcast über den Investor-Bereich auf investor.seer.bio verfolgen, wo auch eine Aufzeichnung nach der Veranstaltung verfügbar sein wird.
- None.
- None.
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
When will Seer (SEER) release Q1 2025 earnings?
What time is Seer's Q1 2025 earnings call?
How can investors access Seer's Q1 2025 earnings webcast?
Will Seer's Q1 2025 earnings call be available for replay?
